Request Sample Form

Name*:

Phone No.*:

Email*:

Service Intersted In:

Download Complete Report

Your Name*:

Email*:

Contact Number*:

Subject*:

Service Interested In* (required)

Your Requirment*:

Boston Beer CEO: We’re looking at cannabis after success of hard seltzer business

The CEO of Boston Beer Company told CNBC on Friday that the brewer is looking to enter the cannabis market next after its success in the hard seltzer business.

August 30th, 2019|News|

Immunicum’s ilixadencel successful in kidney cancer

Immunicum has announced that in a trial, ilixadencel in combination with Pfizer’s Sutent (sunitinib) achieved complete tumour responses in five out of 45 metastatic kidney cancer patients (11%) in contrast to one out of 25 in the sunitinib monotherapy control arm (4%).

August 30th, 2019|News|

AbbVie discontinues Rova-T programme

AbbVie has announced the discontinuation of its Rova-T (rovalpituzumab tesirine) research and development programme, following a failure to demonstrate survival benefit at a pre-planned interim analysis.

August 30th, 2019|News|

DIC to acquire BASF’s worldwide pigments business for $1.3 billion

BASF has announced that DIC Corp. (Tokyo, Japan) will acquire BASF’s worldwide pigments business. The cost of the transaction is €1.15 billion ($1.27 billion) on a debt-free basis.

August 29th, 2019|News|

Quaker Houghton to Acquire Operating Divisions of Norman Hay plc

Quaker Houghton (NYSE: KWR) announced today that it has agreed to acquire the operating divisions of Norman Hay plc, a private UK company that provides specialty chemicals, operating equipment, and services to industrial end markets, for a purchase price of 80 million GBP (~$98 million at current rates), subject to […]

August 29th, 2019|News|

ExxonMobil, Mosaic Materials to explore carbon capture technologies

ExxonMobil and Mosaic Materials have entered into an agreement to explore the advancement of technology to remove carbon dioxide from emissions sources.

August 26th, 2019|News|

Amgen to acquire Otezla® for $13.4 billion in cash

Amgen (NASDAQ: AMGN) announced today that it has entered into an agreement with Celgene Corporation (NASDAQ: CELG) in connection with its previously announced merger with Bristol-Myers Squibb Company (NYSE: BMY) to acquire worldwide rights to Otezla® (apremilast), the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, and certain […]

August 26th, 2019|News|

Australia’s Argosy Minerals inks lithium supply deal with Mitsubishi Corp RtM

Lithium miner Argosy Minerals Ltd said on Friday it has signed a preliminary agreement with a unit of Japan’s Mitsubishi Corp for the supply of lithium carbonate product.

August 23rd, 2019|News|

AstraZeneca agrees to buy US FDA Priority Review Voucher from Sobi

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi). A PRV entitles the holder to FDA priority review of a single New […]

August 23rd, 2019|News|

Scientists develop a new gene-editing tool that could help treat many disorders caused by gene mutations

Researchers have developed a new tool — dubbed SATI — to edit the mouse genome, enabling the team to target a broad range of mutations and cell types. The new genome-editing technology could be expanded for use in a broad range of gene mutation conditions such as Huntington’s disease […]

August 23rd, 2019|News|